[
  {
    "ts": null,
    "headline": "Touchstone Sands Capital Select Growth Fund Q1 2025 Commentary",
    "summary": "The Touchstone Sands Capital Select Growth Fund (Class A) outperformed its benchmark Index for Q1 ended March 31, 2025. Click here to read the full commentary.",
    "url": "https://finnhub.io/api/news?id=650f463e70e6c94c80d5916838b7c9235e96f36db4cb9ac7498aecdeafc77093",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750981800,
      "headline": "Touchstone Sands Capital Select Growth Fund Q1 2025 Commentary",
      "id": 135578732,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2207785362/image_2207785362.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "The Touchstone Sands Capital Select Growth Fund (Class A) outperformed its benchmark Index for Q1 ended March 31, 2025. Click here to read the full commentary. ",
      "url": "https://finnhub.io/api/news?id=650f463e70e6c94c80d5916838b7c9235e96f36db4cb9ac7498aecdeafc77093"
    }
  },
  {
    "ts": null,
    "headline": "VKTX Initiates Phase 3 Study on Obesity Candidate VK2735",
    "summary": "Viking begins phase III VANQUISH program for VK2735, targeting weight loss in obese adults with or without type II diabetes.",
    "url": "https://finnhub.io/api/news?id=5d10ec823b3daa855946f6542920f2895d4999b59cbdfb8a6a63459ff75a4e57",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750950720,
      "headline": "VKTX Initiates Phase 3 Study on Obesity Candidate VK2735",
      "id": 135567398,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Viking begins phase III VANQUISH program for VK2735, targeting weight loss in obese adults with or without type II diabetes.",
      "url": "https://finnhub.io/api/news?id=5d10ec823b3daa855946f6542920f2895d4999b59cbdfb8a6a63459ff75a4e57"
    }
  },
  {
    "ts": null,
    "headline": "Can LLY's Next-Generation Obesity Pipeline Fuel Further Growth?",
    "summary": "Eli Lilly bets on next-generation obesity candidates like orforglipron and retatrutide to sustain growth amid rising competition.",
    "url": "https://finnhub.io/api/news?id=7550352d1723c5240545ddc5df87ea158210be6b9a4521412cad83e52f236ca9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750945380,
      "headline": "Can LLY's Next-Generation Obesity Pipeline Fuel Further Growth?",
      "id": 135578939,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly bets on next-generation obesity candidates like orforglipron and retatrutide to sustain growth amid rising competition.",
      "url": "https://finnhub.io/api/news?id=7550352d1723c5240545ddc5df87ea158210be6b9a4521412cad83e52f236ca9"
    }
  },
  {
    "ts": null,
    "headline": "Ozempic-maker Novo Nordisk's shares under growing pressure",
    "summary": "Novo Nordisk shares have come under pressure amid weight-loss drug competition, while UK health officials have launched a study into a side effect of the jabs.",
    "url": "https://finnhub.io/api/news?id=1bf926c5ec4b52ec3469b700a20765835d5aecb18becfdcb6dd9a987930ef231",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750944461,
      "headline": "Ozempic-maker Novo Nordisk's shares under growing pressure",
      "id": 135558695,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk shares have come under pressure amid weight-loss drug competition, while UK health officials have launched a study into a side effect of the jabs.",
      "url": "https://finnhub.io/api/news?id=1bf926c5ec4b52ec3469b700a20765835d5aecb18becfdcb6dd9a987930ef231"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly: I've Learned Not To Fight Against The Market (Downgrade)",
    "summary": "Eli Lilly: I've Learned Not To Fight Against The Market (Downgrade)",
    "url": "https://finnhub.io/api/news?id=8e8be7919b7c28620d9991337d3ad8537c775092ca6c1025d0a7ba803b607dd7",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750939237,
      "headline": "Eli Lilly: I've Learned Not To Fight Against The Market (Downgrade)",
      "id": 135560215,
      "image": "",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=8e8be7919b7c28620d9991337d3ad8537c775092ca6c1025d0a7ba803b607dd7"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly receives FDA approval for Amyvid label update",
    "summary": "The new label changes include revised usage guidelines to estimate plaque density.",
    "url": "https://finnhub.io/api/news?id=2de507ff1d562009159b17871a5c3f80f7a8b69e19c0fb64c266c822b1adfc9e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750937465,
      "headline": "Eli Lilly receives FDA approval for Amyvid label update",
      "id": 135558696,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The new label changes include revised usage guidelines to estimate plaque density.",
      "url": "https://finnhub.io/api/news?id=2de507ff1d562009159b17871a5c3f80f7a8b69e19c0fb64c266c822b1adfc9e"
    }
  },
  {
    "ts": null,
    "headline": "Lilly to launch Mounjaro pen in India as Novo rivalry heats up in mega market",
    "summary": "June 26 - India's drug regulator on Thursday approved the launch of pre-filled injector pens of Eli Lilly'sblockbuster weight-loss drug, Mounjaro, giving...",
    "url": "https://finnhub.io/api/news?id=cd81c40fc237451184301bac58ac83049cc6b9514027c8594d06a17c3680e087",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750936898,
      "headline": "Lilly to launch Mounjaro pen in India as Novo rivalry heats up in mega market",
      "id": 135559740,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "June 26 - India's drug regulator on Thursday approved the launch of pre-filled injector pens of Eli Lilly'sblockbuster weight-loss drug, Mounjaro, giving...",
      "url": "https://finnhub.io/api/news?id=cd81c40fc237451184301bac58ac83049cc6b9514027c8594d06a17c3680e087"
    }
  },
  {
    "ts": null,
    "headline": "Lilly to launch Mounjaro pen in India to compete with Novo's weight-loss drug Wegovy",
    "summary": "HYDERABAD (Reuters) -Eli Lilly said on Thursday that India's drug regulator had approved the launch of pre-filled injector pens of its blockbuster weight-loss drug, Mounjaro, giving it more options to compete with Novo Nordisk's recently launched Wegovy.  Lilly started selling Mounjaro in India in late March for diabetes and obesity, and it was so far available only in 2.5 mg and 5 mg vials.  \"With this approval, all six dosage options for Mounjaro will soon be available in India, supporting a more personalized approach to treatment,\" Lilly India President Winselow Tucker said.",
    "url": "https://finnhub.io/api/news?id=0abc1f82d652b2222306eb2ed90c1c0cf7bd4b71fe51fe64add451dfb9e08f66",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750923923,
      "headline": "Lilly to launch Mounjaro pen in India to compete with Novo's weight-loss drug Wegovy",
      "id": 135553007,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "HYDERABAD (Reuters) -Eli Lilly said on Thursday that India's drug regulator had approved the launch of pre-filled injector pens of its blockbuster weight-loss drug, Mounjaro, giving it more options to compete with Novo Nordisk's recently launched Wegovy.  Lilly started selling Mounjaro in India in late March for diabetes and obesity, and it was so far available only in 2.5 mg and 5 mg vials.  \"With this approval, all six dosage options for Mounjaro will soon be available in India, supporting a more personalized approach to treatment,\" Lilly India President Winselow Tucker said.",
      "url": "https://finnhub.io/api/news?id=0abc1f82d652b2222306eb2ed90c1c0cf7bd4b71fe51fe64add451dfb9e08f66"
    }
  },
  {
    "ts": null,
    "headline": "5 Revealing Analyst Questions From Eli Lilly’s Q1 Earnings Call",
    "summary": "Eli Lilly’s first quarter saw rapid revenue growth, but the market responded negatively due to profit shortfalls and emerging competitive pressures. Management credited the surge in sales to the continued success of its diabetes and obesity medicines, particularly Mounjaro and Zepbound, which now account for a significant portion of total revenue. However, executives also acknowledged that higher marketing and R&D spending, as well as elevated costs tied to launching new products and acquiring l",
    "url": "https://finnhub.io/api/news?id=b0fa7d3c124cac5898c2c22b020dcd62b2cf83e7ee57e342f1603c10edcb8ccd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750921147,
      "headline": "5 Revealing Analyst Questions From Eli Lilly’s Q1 Earnings Call",
      "id": 135558697,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly’s first quarter saw rapid revenue growth, but the market responded negatively due to profit shortfalls and emerging competitive pressures. Management credited the surge in sales to the continued success of its diabetes and obesity medicines, particularly Mounjaro and Zepbound, which now account for a significant portion of total revenue. However, executives also acknowledged that higher marketing and R&D spending, as well as elevated costs tied to launching new products and acquiring l",
      "url": "https://finnhub.io/api/news?id=b0fa7d3c124cac5898c2c22b020dcd62b2cf83e7ee57e342f1603c10edcb8ccd"
    }
  },
  {
    "ts": null,
    "headline": "Victory Diversified Stock Fund Q1 2025 Commentary",
    "summary": "In the first quarter, the Victory Diversified Stock Fund A-Shares (without sales charge) underperformed its S&P 500Â®Index benchmark by 95 basis points.",
    "url": "https://finnhub.io/api/news?id=e24c741fcfd4e69f1d780d535565edcb9e22315ebcd90aa2aa6c1dbb7547c944",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750920900,
      "headline": "Victory Diversified Stock Fund Q1 2025 Commentary",
      "id": 135552014,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2149332829/image_2149332829.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "In the first quarter, the Victory Diversified Stock Fund A-Shares (without sales charge) underperformed its S&P 500Â®Index benchmark by 95 basis points.",
      "url": "https://finnhub.io/api/news?id=e24c741fcfd4e69f1d780d535565edcb9e22315ebcd90aa2aa6c1dbb7547c944"
    }
  },
  {
    "ts": null,
    "headline": "Victory Munder Multi-Cap Fund Q1 2025 Commentary",
    "summary": "Victory Munder Multi-Cap Fund Q1 2025 Commentary",
    "url": "https://finnhub.io/api/news?id=54acc3b2032ea85e7556dc7c5b6f6440d00ca914fdf695841f823d2c5501ecb1",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750919880,
      "headline": "Victory Munder Multi-Cap Fund Q1 2025 Commentary",
      "id": 135550691,
      "image": "",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=54acc3b2032ea85e7556dc7c5b6f6440d00ca914fdf695841f823d2c5501ecb1"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly: FDA expands Amyvid indication in the US",
    "summary": "Eli Lilly announces that the Food and Drug Administration has approved updated labeling for Amyvid , an injectable agent used in brain imaging to estimate the density of amyloid plaques in patients...",
    "url": "https://finnhub.io/api/news?id=0c41f9f8b3c6753aa3b8d9ad8ae86dc159ea2b80a2a574adcee7033fe3571da8",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750917030,
      "headline": "Eli Lilly: FDA expands Amyvid indication in the US",
      "id": 135547091,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "Eli Lilly announces that the Food and Drug Administration has approved updated labeling for Amyvid , an injectable agent used in brain imaging to estimate the density of amyloid plaques in patients...",
      "url": "https://finnhub.io/api/news?id=0c41f9f8b3c6753aa3b8d9ad8ae86dc159ea2b80a2a574adcee7033fe3571da8"
    }
  },
  {
    "ts": null,
    "headline": "AMG Montrusco Bolton Large Cap Growth Fund Q1 2025 Commentary",
    "summary": "AMG Montrusco Bolton Large Cap Growth Fund Q1 2025 Commentary",
    "url": "https://finnhub.io/api/news?id=1c474c655ef68acd9258781d828a7d18578ea24ef5df7ceda1fb3eb71bdb923a",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750916700,
      "headline": "AMG Montrusco Bolton Large Cap Growth Fund Q1 2025 Commentary",
      "id": 135546973,
      "image": "",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=1c474c655ef68acd9258781d828a7d18578ea24ef5df7ceda1fb3eb71bdb923a"
    }
  }
]